Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide

Show other versions (1)

© 2019 American Pharmacists Association® Oral semaglutide, which has undergone multiple phase 3 clinical trials, represents the first oral biologic medication for type 2 diabetes in the form of a daily capsule. It provides similar efficacy compared with its weekly injection counterpart, but it deman...

Full description

Bibliographic Details
Main Authors:	Abramson, Alex (Author), Halperin, Florencia (Author), Kim, Jane (Author), Traverso, Carlo Giovanni (Author)
Other Authors:	Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Massachusetts Institute of Technology. Department of Mechanical Engineering (Contributor)
Format:	Article
Language:	English
Published:	Elsevier BV, 2022-02-23T21:07:16Z.
Subjects:	Article
Online Access:	Get fulltext

Similar Items

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
by: Abramson, Alex, et al.
Published: (2022)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
by: Chapman, R.H, et al.
Published: (2021)

Oral delivery of biologics using drug-device combinations
by: Caffarel Salvador, Ester, et al.
Published: (2020)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
by: Ann Mertens, et al.
Published: (2020-12-01)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
by: Ping Zhong, et al.
Published: (2021-10-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021-09-01)

Acute Kidney Injury Associated With Semaglutide
by: David J. Leehey, et al.
Published: (2021-03-01)

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
by: Paul Langley
Published: (2020-02-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics
by: Coffey, Jacob William, et al.
Published: (2022)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
by: Gomez-Peralta F, et al.
Published: (2019-02-01)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
by: Hwi Seung Kim, et al.
Published: (2021-09-01)

Farmakologisk behandling vid fetma : Semaglutid versus liraglutid
by: Nilsson, Natalié
Published: (2021)

Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics
by: Coffey, Jacob William, et al.
Published: (2022)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
by: Jan Maurik van den Heuvel, et al.
Published: (2020-04-01)

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China
by: Shanshan Hu, et al.
Published: (2021-06-01)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
by: Michael E Røder
Published: (2019-12-01)

The opportunities & challenges in delivering oral cholera vaccines
by: Jacqueline Deen, et al.
Published: (2016-01-01)

Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease
by: Hongzhi Qiao, et al.
Published: (2017-01-01)

Individual Oral Therapy with Immediate Release and Effervescent Formulations Delivered by the Solid Dosage Pen
by: Klaus Wening, et al.
Published: (2012-11-01)

Oral Biology, Oral Pathology, and Oral Treatments
by: Samir Nammour, et al.
Published: (2016-01-01)

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
by: Xin Zhang, et al.
Published: (2021-07-01)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
by: Hassan A. Alsugair, et al.
Published: (2021-08-01)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
by: Rafael Simó, et al.
Published: (2021-07-01)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
by: Damas-Fuentes, M., et al.
Published: (2022)

Development and characterisation of semisolid systems to deliver propolis in the oral cavity
by: A.N. Hirata, et al.
Published: (2010-01-01)

Oral Health Information Being Delivered to Yazd Population in 2011
by: Ahmad Haerian, et al.
Published: (2013-06-01)

FDI Vision 2030: Delivering Optimal Oral Health for All
by: Michael Glick, et al.
Published: (2021-02-01)

An ingestible self-orienting system for oral delivery of macromolecules
by: Abramson, Alex, et al.
Published: (2020)

"Inactive" ingredients in oral medications
by: Reker, Daniel, et al.
Published: (2020)

nitiatives to Improve Safety of Oral Anticancer Agents Delivered by Community Pharmacists
by: Klaus Meier, et al.
Published: (2020-10-01)

Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system
by: Al-Kurdi ZI, et al.
Published: (2015-11-01)

The genre of the body of oral presentations delivered by english for workplace communication students
by: Seliman, Salbiah, et al.
Published: (2010)

The Barriers and Facilitators to Deliver Oral Care for Older Adults in Hospital Settings
by: Oda, Keiko
Published: (2019)

Cannot write session to /tmp/vufind_sessions/sess_okhpufoh8lmgngqfhv8ka8acmu